Locally Advanced Head and Neck Squamous Cell Carcinoma
Oncology·MeSH: Squamous Cell Carcinoma of Head and Neck
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Volrustomig | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Locally Advanced Head and Neck Squamous Cell Carcinoma?
BioSniper tracks 1 drug in development for Locally Advanced Head and Neck Squamous Cell Carcinoma across 1 company.
How many clinical trials target Locally Advanced Head and Neck Squamous Cell Carcinoma?
There are 3 clinical trials targeting Locally Advanced Head and Neck Squamous Cell Carcinoma tracked by BioSniper.
What is the prevalence of Locally Advanced Head and Neck Squamous Cell Carcinoma?
The estimated prevalence of Locally Advanced Head and Neck Squamous Cell Carcinoma is approximately 14.0 per 100,000 population.
Deep-dive into Locally Advanced Head and Neck Squamous Cell Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis